No Data
No Data
Ford, Envista Holdings, and Alaska Air Are Among Additions to GS' Short Duration List
Has Royalty Pharma Plc (NASDAQ:RPRX) Stock's Recent Performance Got Anything to Do With Its Financial Health?
Most readers would already know that Royalty Pharma's (NASDAQ:RPRX) stock increased by 4.4% over the past three months. As most would know, long-term fundamentals have a strong correlation with mark
Teva Upgraded at J.P. Morgan on Upcoming Catalysts
Royalty Pharma to Present at TD Cowen's 44th Annual Health Care Conference
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in a fireside chat at TD Cowen's 44th Annual Health Care Conference on March 5, 2024 at 10:30 a.m.
There May Be Underlying Issues With The Quality Of Royalty Pharma's (NASDAQ:RPRX) Earnings
Royalty Pharma plc's (NASDAQ:RPRX) robust earnings report didn't manage to move the market for its stock. We did some digging, and we found some concerning factors in the details. NasdaqGS:RPRX Ea
JPMorgan Cuts Price Target on Royalty Pharma to $42 From $45, Keeps Overweight Rating
Royalty Pharma (RPRX) has an average rating of buy and price targets ranging from $37 to $60, according to analysts polled by Capital IQ. Price: 30.13, Change: +0.21, Percent Change: +0.70
No Data